Summary of use during lactation
There are no reports of breastfeeding after prademagene zamikeracel therapy. If the mother requires prademagene zamikeracel therapy, it is not necessarily a reason to discontinue breastfeeding. However, the benefits of breastfeeding to the mother and infant should be considered along with potential adverse effects on the breastfed infant from prademagene zamikeracel, such as potential retroviral vector-mediated insertional oncogenesis.
Drug levels in milk and infant serum
Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
Relevant published information was not found as of the revision date.
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.